
Biogen and Ionis report positive topline clinical data on investigational Alzheimer’s disease treatment at AAIC
CAMBRIDGE, Mass. and CARLSBAD, Calif.: CAMBRIDGE, Mass. and CARLSBAD, Calif., July 26, 2021 /PRNewswire/ — Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that topline data from a Phase 1b placebo-controlled, multiple ascending dose clinical study showed that BIIB080/IONIS-MAPTRx met its primary objective of safety and… Click here to view original post… […]